Dernières nouvelles pour Kyndryl Hldgs (NYSE:KD) Stock

Kyndryl Hldgs

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

UBS analyst Batya Levi maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Buy and raises the price target from $280 to $285.

News

Price Target

Analyst Ratings

SBAC

UBS Maintains Buy on SBA Communications, Raises Price Target to $285

Guggenheim analyst Gregory Francfort maintains Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) with a Buy and lowers the price target from $18 to $17.

PTLO

Guggenheim Maintains Buy on Portillos, Lowers Price Target to $17

UBS analyst Brent Dilts maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Buy and raises the price target from $106 to $120.

UBS Maintains Buy on Prologis, Raises Price Target to $120

Deutsche Bank analyst Scott Deuschle downgrades Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Buy to Hold and lowers the price target from $580 to $542.

Downgrades

Deutsche Bank Downgrades Northrop Grumman to Hold, Lowers Price Target to $542

UBS analyst Alex Kramm maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Buy and raises the price target from $655 to $700.

MSCI

UBS Maintains Buy on MSCI, Raises Price Target to $700

Guggenheim analyst Howard Ma downgrades Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from Neutral to Sell and announces $105 price target.

DDOG

Guggenheim Downgrades Datadog to Sell, Announces $105 Price Target

Deutsche Bank analyst Scott Deuschle downgrades BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) from Buy to Hold and raises the price target from $119 to $150.

BWXT

Deutsche Bank Downgrades BWX Technologies to Hold, Raises Price Target to $150

Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>).
The deal consideration of up to $25 million includes an upfront equity payment of $7.5 million and near-term milestones.
With the upfront payment, Rallybio expects its cash runway to extend into mid-2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44697139/nano-cap-rallybio-stops-mid-stage-program-for-pediatric-bleeding-disorder-on-disappointing-efficacy-stock-plunges" rel="noreferrer noopener">Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints</a>
The REV102 program, which originated from a joint venture between Rallybio and Recursion, focused on discovering and developing novel, orally available small-molecule inhibitors of ENPP1 for treating patients with HPP.
HPP is a rare, inherited metabolic bone disease caused by a deficiency in the enzyme alkaline phosphatase (ALP).
This deficiency disrupts the mineralization of bones and teeth, leading to a range of skeletal and dental abnormalities.
The lead candidate from the joint venture, REV102, entered into IND-enabling <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46292987/rallybio-sells-interest-in-rev102-program-to-recursion-pharmaceuticals" rel="noreferrer noopener">studies in early 2025</a>.
Under the terms of the agreement, Rallybio is eligible to receive certain payments, including $7.5 million in upfront equity, a contingent equity payment of $12.5 million upon the initiation of additional preclinical studies, and a $5 million milestone payment in connection with the initiation of dosing in a Phase 1 clinical study, as defined in the agreement.
Rallybio is also eligible to receive low single-digit royalties on all future net sales by Recursion. In addition, Rallybio may be eligible to receive certain payments in the event of Recursion&#8217;s sale of the REV102 program.
Recursion Pharmaceuticals announced a reduction in personnel and infrastructure to extend <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45864493/recursion-pharmaceuticals-stock-is-up-10-today-whats-happening" rel="noreferrer noopener">its cash runway in June</a>.
The company announced an approximately 20% reduction in its workforce, extending its cash runway into the fourth quarter of 2027.
The Nvidia-backed biotech company expects its cash burn to be below $450 million in 2025 and under $390 million in 2026.
Price Action: At the last check on Tuesday, RLYB stock was up 36.8% at $0.47, and RXRX stock was up 0.81% at $4.97 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies" target="_blank" rel="noreferrer noopener">Novartis Gets Swiss Approval For First Malaria Drug For Babies</a></li>
</ul>
Photo: Shutterstock

Biotech

Penny Stocks

Health Care

Movers

Trading Ideas

General

RLYB

RXRX

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) has made a decisive pivot away from Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), converting its entire treasury to Ethereum and accumulating roughly 100,000 ETH <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46202593/bitmine-bmnr-stock-soars-as-it-pivots-to-ethereum-treasury-appoints-tom-lee-chairman">on its balance sheet.</a>
What Happened: Speaking to CNBC on Monday, CEO Sam Tabar <a href="https://www.youtube.com/watch?v=1zGjJGzm8qM">described </a>Ethereum as "alive," "institutional," and "the only blockchain capable of rewriting the financial system."
"We sold a profitable business—we exited Bitcoin mining," Tabar said. "We took the cash on our balance sheet, sold all our Bitcoin, and did this raise. I actually personally participated in that raise myself with my own savings, and we poured that all into Ethereum."
With $172 million in capital raised and over 417 Bitcoin liquidated, the firm has now fully embraced an Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-only treasury strategy. 
According to Tabar, this isn't just about asset exposure—it's about investing in a programmable economic engine.
"Ethereum represents that next wave," Tabar said. "We&#8217;re not just buying a coin. We&#8217;re putting our reserves into a protocol that powers trillions of on-chain activity."
Citing Ethereum's dominance in developer activity, smart contract programmability, and real-world asset tokenization, Tabar argued that Ethereum is becoming a new type of corporate treasury asset, akin to gold or bonds, but dynamic. 
"Ethereum is alive. It moves with technological innovation," he said.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46251827/crypto-tax-loopholes-closing-a-look-inside-bitcoin-senator-lummis-new-bill">Crypto Tax Loopholes Closing? A Look Inside &#8216;Bitcoin Senator&#8217; Lummis&#8217; New Bill</a>
Tabar stressed Ethereum's unique ability to capture real economic value through transaction fees, something he claims Bitcoin cannot replicate. 
"Stablecoin volumes, tokenization, all of that flows back to ETH holders. Bitcoin does not participate in that feedback loop."
He also praised Ethereum's position in institutional infrastructure. 
"There is no second best," he said, referencing Robinhood's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) recent move to tokenize stocks on Ethereum via Arbitrum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ARB</a>). "Eventually Ethereum will eat the financial world. It will be the basic infrastructure layer to transfer value between parties without escrow agents."
Why It Matters: Bit Digital's pivot comes amid a broader revival of institutional interest in Ethereum.
Ether ETFs, once feared to be "zombie funds," saw $40 million in inflows in June, including from BlackRock's iShares Ethereum Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>). 
Tabar attributes the shift to regulatory clarity.
"There's a much more friendly SEC outlook with respect to projects on the Ethereum blockchain," he said, pointing to legislation like the Genius Act and the proposed Clarity Act, which classify Ethereum as a commodity. "Gary Gensler is gone. That has unleashed Ethereum for adoption by institutions."
While ETFs offer passive ETH exposure, Bit Digital's model adds yield through staking. "You can't stake your ETH in an ETF," Tabar said. "We can stake our ETH and generate a real return on our holdings—currently around 3%—and that compounds."
He added, "That's a much more efficient way to access Ethereum's economic upside through a public vehicle like BTBT."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46248538/bitcoin-ethereum-solana-treasury-companies-need-to-manage-market-volatility-franklin-templeton-report-warns">Bitcoin, Ethereum, Solana Treasury Companies Need To Manage Market Volatility, Franklin Templeton Report Warns</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ARB

$BTC

$ETH

BTBT

ETHA

HOOD

Bitcoin Miner Bit Digital Dumped All Its BTC For ETH—And Isn't Looking Back

<a href="https://www.cnbc.com/2025/07/08/robinhood-ceo-downplays-openai-concerns-on-tokenized-stock-structure.html">https://www.cnbc.com/2025/07/08/robinhood-ceo-downplays-openai-concerns-on-tokenized-stock-structure.html</a>

MSFT

'Robinhood CEO downplays OpenAI concerns on tokenized stock structure'- CNBC

UBS analyst Robin Farley maintains MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Neutral and raises the price target from $37 to $42.

UBS Maintains Neutral on MGM Resorts International, Raises Price Target to $42

NDRA

ENDRA Life Sciences Shares Halted On Circuit Breaker To The Downside, Stock Now Up 191.9%

UBS analyst Alex Kramm maintains Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Neutral and raises the price target from $445 to $515.

UBS Maintains Neutral on Moodys, Raises Price Target to $515

Orion Plans To Discontinue Production At Three To Five Of Its Carbon Black Lines At Multiple Facilities In Americas And EMEA By 2025 End

As Amphenol Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) trades near its 52-week high, the company finds itself at a pivotal moment in an ever-evolving tech landscape. With a 42% surge in stock value this year, outpacing the broader S&amp;P 500 Information Technology Sector Index, Amphenol&#8217;s recent fiscal first-quarter results reveal robust demand for its advanced interconnect solutions, particularly in burgeoning markets such as IT <a href="https://www.benzinga.com/topic/technology-stocks">datacom and mobile devices.</a>
Amphenol designs, manufactures, and markets advanced interconnect, sensor, and antenna solutions worldwide. The company offers a range of products, including electrical, electronic, and fiber optic connectors, antennas, sensors, and specialty cables, for automotive, aerospace, communications, and industrial applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/05/45261116/cisco-unveils-quantum-chip-and-lab-to-push-next-gen-networking" rel="noreferrer noopener">Cisco Unveils Quantum Chip And Lab To Push Next-Gen Networking</a>
On April 23, Amphenol reported <a href="https://www.benzinga.com/news/earnings/25/04/44950358/amphenol-q1-earnings-48-topline-growth-driven-by-it-mobile-defense-sectors" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2025</a> sales growth of 48% year-over-year to $4.81 billion, surpassing the analyst consensus estimate of $4.23 billion and the company&#8217;s estimate of $4.00 billion to $4.10 billion. On Jan. 22, the company reported <a href="https://www.benzinga.com/news/earnings/25/01/43130244/amphenol-q4-earnings-30-sales-growth-ceo-highlights-growth-in-it-mobile-and-defense-markets-forecasts-strong-q1-sales-growth" target="_blank" rel="noreferrer noopener">fourth-quarter topline</a> growth of 30% Y/Y to $4.32 billion, topping the analyst consensus estimate of $4.07 billion. 
Organic growth in the IT datacom market and robust organic growth in the mobile devices, defense, and communications networks markets, together with contributions from the company&#8217;s acquisition program, drove the topline growth. The adjusted operating margin for the quarter reached a record 21.3%, up from 21.0% in the same quarter last year.
Amphenol expects second-quarter sales to be between $4.90 billion and $5.00 billion. This represents a 36%-39% increase over the prior-year quarter, and the street view pegs expectations at $4.58 billion.
On March 17, JPMorgan analyst Samik Chatterjee flagged Amphenol as one of the companies <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44362565/why-nvidias-next-moves-matter-for-amphenol-dell-super-micro" target="_blank" rel="noreferrer noopener">poised to benefit</a> from Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell Ultra ramp. While the adoption of optics remains a concern, analysts expect copper to continue dominating in-rack connectivity—a positive sign for Amphenol. Amphenol, with its intense exposure to passive copper, along with Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), and Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>), is likely to draw attention as the AI wave builds, according to the analyst.
Nineteen analysts have set a <a target="_blank" href="https://www.benzinga.com/quote/APH/analyst-ratings" rel="noreferrer noopener">consensus price target</a> of $92.50 for Amphenol. Recent ratings from Goldman Sachs, Evercore ISI Group, and UBS average a target of $104.33, indicating a potential upside of 5.55% for the stock.
Price Action: APH stock is down 0.23% to $98.32 during early trading on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46278679/will-recent-events-dent-palantir-technologies-stock-385-growth" target="_blank" rel="noreferrer noopener">Will Recent Events Dent Palantir Technologies Stock 385% Growth?</a></li>
</ul>
Photo: Shutterstock

Tech

COHR

LITE

NVDA

Amphenol Soars 42% To 52-Week High Riding AI Wave

UBS analyst Robin Farley maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Neutral and raises the price target from $43 to $48.

UBS Maintains Neutral on Las Vegas Sands, Raises Price Target to $48

UBS analyst Rodrigo Alcantara maintains Coca-Cola Femsa SAB de (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) with a Buy and raises the price target from $109 to $113.

UBS Maintains Buy on Coca-Cola Femsa SAB de, Raises Price Target to $113

UBS analyst Alex Kramm maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Buy and raises the price target from $195 to $210.

UBS Maintains Buy on Intercontinental Exchange, Raises Price Target to $210

<ul>
<li>Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) for HIV treatment and assess experiences of using Apretude (cabotegravir long-acting (CAB LA) for PrEP)in range of populations</li>
<li>New phase IIIb data look at preferences among treatment-naive adults offered the choice to switch to CAB+RPV LA after attaining rapid viral suppression with Dovato (DTG/3TC) daily oral therapy</li>
<li>Interim data from wave three of the Positive Perspectives study demonstrate impact of joint decision-making on HIV treatment satisfaction and health outcomes</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of abstracts from its innovative HIV treatment and prevention portfolio at the International AIDS Society 2025 Conference (IAS 2025) in Kigali, Rwanda. Key data will highlight the long-term effectiveness of Vocabria &amp; Rekambys, (branded as Cabenuva in the US, Canada and Australia) the company's complete long-acting injectable regimen for treatment; evaluate patient preference for long-acting injectables compared to daily oral therapy; and measure benefits of long-acting injectables in tackling common challenges associated with taking daily pills, including stigma and adherence.

ViiV Healthcare Showcases Data At IAS 2025 Highlighting Long-Term Effectiveness And Patient Preference For Long-Acting HIV Injectables Vocabria + Rekambys And Apretude Over Daily Oral Therapy

UBS analyst Batya Levi maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Buy and raises the price target from $118 to $124.

UBS Maintains Buy on Crown Castle, Raises Price Target to $124

Press Releases

Rosen Law Firm Encourages Kyndryl Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - KD

Kyndryl Announces €100 Million Data, AI and Cyber Resilience Investment in France

Legal

Kyndryl Investor News: If You Have Suffered Losses in Kyndryl Holdings, Inc. (NYSE: KD), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Contracts

Kyndryl Modernizes the Virginia Department of Motor Vehicles' IT Systems to Transform the Customer Experience

KYNDRYL TO SPEAK AT BANK OF AMERICA INVESTOR CONFERENCE ON JUNE 3

Kyndryl Report: Why Most Businesses Are Not Yet Winning With AI

Kyndryl Announces Global Strategic Alliance with Databricks to Drive Customers' Digital Transformation

Kyndryl launches mainframe modernization services leveraging AWS's agentic AI capabilities

Commvault Announces Partnership with Kyndryl to Deliver Incident Recovery Services

Small Cap

Opinion

Geopolitics, Quantum Risk, and AI Attacks: Why Cybersecurity Is Being Rewritten

CSE:SCPE

CVLT

CYBHD

CYBHF

SCPCF

TSXV:CYBE

Accenture plc Class A Ordinary Shares (Ireland)

Accenture

ASGN

Alpha Technology Group Limited - Class A Ordinary Shares

Alpha Technology Group

BigBear.ai Hldgs

CI&T

CISO Global

Castellum

Cognizant Technology Solutions Corporation - Class A Common Stock

Cognizant Tech Solns

Endava plc American Depositary Shares (each representing one Class A Ordinary Share)

Comments

Kyndryl Hldgs

Actualités

Dernières nouvelles pour Kyndryl Hldgs (NYSE:KD) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL